When J&J CEO Gorsky says, "We're not just sitting back, we're making aggressive moves in areas such as e-commerce, investments in that shift," his words are music to analysts' ears. J&J has OTC drug and other consumer health brands to drive growth, but it's missing the digital piece, they say.
Johnson & Johnson didn't disappoint analysts by announcing, following flat consumer health revenues in the fourth quarter, it is investing in making its segment more competitive in a market swinging more toward online sales.
"The shift to e-commerce, shift in some cases to more natural brands, digital types of brands," says CEO Alex Gorsky,...
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
To help sponsors developing candidate mpox vaccines, the World Health Organization will soon be finalizing guidance on the preferred and minimum characteristics these products must satisfy regarding efficacy, dose regimen and other aspects to secure regulatory approval.
The WHO’s emergency committee has warned of a lack of understanding of the epidemiology of mpox, the limited availability of vaccines, and the complexities of donations and procurement.
An ongoing collaborative initiative involving global regulators assessing post-approval manufacturing changes has highlighted the need to establish a standardized platform that can facilitate the submission and regulatory evaluation of such changes.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
